• 1
    Prusiner SB ( 1998) Prions. Proc Natl Acad Sci USA 95: 1336313383.
  • 2
    Chesebro B ( 1999) Prion protein and the transmissible spongiform encephalopathy diseases. Neuron 24: 503506.
  • 3
    Prusiner SB ( 1982) Novel proteinaceous infectious particles cause scrapie. Science 216: 136144.
  • 4
    O'Riordan JF, Goldstick TK, Ditzel J, Ernest JT ( 1983) Characterization of oxygen-hemoglobin equilibrium curves using nonlinear regression of the Hill equation: parameter values for normal human adults. Adv Exp Med Biol 159: 435444.
  • 5
    Harrison PM, Bamborough P, Daggett V, Prusiner SB, Cohen FE ( 1997) The prion folding problem. Curr Opin Struct Biol 7: 5359.
  • 6
    Kuwata K, Nishida N, Matsumoto T, Kamatari YO, Hosokawa-Muto J, Kodama K, Nakamura HK, Kimura K, Kawasaki M, Takakura Y, Shirabe S, Takata J, Kataoka Y, Katamine S ( 2007) Hot spots in prion protein for pathogenic conversion. Proc Natl Acad Sci USA 104: 1192111926.
  • 7
    Hosokawa-Muto J, Kamatari YO, Nakamura HK, Kuwata K ( 2009) Variety of antiprion compounds discovered through an in silico screen based on cellular-form prion protein structure: Correlation between antiprion activity and binding affinity. Antimicrob Agents Chemother 53: 765771.
  • 8
    Kimura T, Hosokawa-Muto J, Kamatari YO, Kuwata K ( 2011) Synthesis of GN8 derivatives and evaluation of their antiprion activity in TSE-infected cells. Bioorg Med Chem Lett 21: 15021507.
  • 9
    Kimura T, Hosokawa-Muto J, Asami K, Murai T, Kuwata K ( 2011) Synthesis of 9-substituted 2,3,4,9-tetrahydro-1H-carbazole derivatives and evaluation of their anti-prion activity in TSE-infected cells. Eur J Med Chem 46: 56755679.
  • 10
    Doh-Ura K, Iwaki T, Caughey B ( 2000) Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol 74: 48944897.
  • 11
    Perrier V, Wallace AC, Kaneko K, Safar J, Prusiner SB, Cohen FE ( 2000) Mimicking dominant negative inhibition of prion replication through structure-based drug design. Proc Natl Acad Sci USA 97: 60736078.
  • 12
    Kocisko DA, Baron GS, Rubenstein R, Chen J, Kuizon S, Caughey B ( 2003) New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products. J Virol 77: 1028810294.
  • 13
    Korth C, May BC, Cohen FE, Prusiner SB ( 2001) Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci USA 98: 98369841.
  • 14
    Caughey B, Ernst D, Race RE ( 1993) Congo red inhibition of scrapie agent replication. J Virol 67: 62706272.
  • 15
    Rambold AS, Miesbauer M, Olschewski D, Seidel R, Riemer C, Smale L, Brumm L, Levy M, Gazit E, Oesterhelt D, Baier M, Becker CF, Engelhard M, Winklhofer KF, Tatzelt J ( 2008) Green tea extracts interfere with the stress-protective activity of PrP and the formation of PrP. J Neurochem 107: 218229.
  • 16
    Doh-ura K, Ishikawa K, Murakami-Kubo I, Sasaki K, Mohri S, Race R, Iwaki T ( 2004) Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J Virol 78: 49995006.
  • 17
    Tsuboi Y, Doh-Ura K, Yamada T ( 2009) Continuous intraventricular infusion of pentosan polysulfate: clinical trial against prion diseases. Neuropathology 29: 632636.
  • 18
    Kimata A, Nakagawa H, Ohyama R, Fukuuchi T, Ohta S, Doh-ura K, Suzuki T, Miyata N ( 2007) New series of antiprion compounds: pyrazolone derivatives have the potent activity of inhibiting protease-resistant prion protein accumulation. J Med Chem 50: 50535056.
  • 19
    Sigurdsson EM, Brown DR, Alim MA, Scholtzova H, Carp R, Meeker HC, Prelli F, Frangione B, Wisniewski T ( 2003) Copper chelation delays the onset of prion disease. J Biol Chem 278: 4619946202.
  • 20
    Thompson MJ, Borsenberger V, Louth JC, Judd KE, Chen B ( 2009) Design, synthesis, and structure-activity relationship of indole-3-glyoxylamide libraries possessing highly potent activity in a cell line model of prion disease. J Med Chem 52: 75037511.
  • 21
    Kuwata K, Kamatari YO, Akasaka K, James TL ( 2004) Slow conformational dynamics in the hamster prion protein. Biochemistry 43: 44394446.
  • 22
    Nakajima M, Yamada T, Kusuhara T, Furukawa H, Takahashi M, Yamauchi A, Kataoka Y ( 2004) Results of quinacrine administration to patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord 17: 158163.
  • 23
    Milhavet O, McMahon HE, Rachidi W, Nishida N, Katamine S, Mange A, Arlotto M, Casanova D, Riondel J, Favier A, Lehmann S ( 2000) Prion infection impairs the cellular response to oxidative stress. Proc Natl Acad Sci USA 97: 1393713942.
  • 24
    Vogtherr M, Grimme S, Elshorst B, Jacobs DM, Fiebig K, Griesinger C, Zahn R ( 2003) Antimalarial drug quinacrine binds to C-terminal helix of cellular prion protein. J Med Chem 46: 35633564.
  • 25
    Telling GC, Scott M, Mastrianni J, Gabizon R, Torchia M, Cohen FE, DeArmond SJ, Prusiner SB ( 1995) Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell 83: 7990.
  • 26
    Masel J, Genoud N, Aguzzi A ( 2005) Efficient inhibition of prion replication by PrP-Fc(2) suggests that the prion is a PrP(Sc) oligomer. J Mol Biol 345: 12431251.
  • 27
    Wille H, Zhang GF, Baldwin MA, Cohen FE, Prusiner SB ( 1996) Separation of scrapie prion infectivity from PrP amyloid polymers. J Mol Biol 259: 608621.
  • 28
    Pham N, Yin S, Yu S, Wong P, Kang SC, Li C, Sy MS ( 2008) Normal cellular prion protein with a methionine at position 129 has a more exposed helix 1 and is more prone to aggregate. Biochem Biophys Res Commun 368: 875881.
  • 29
    Lamberto GR, Binolfi A, Orcellet ML, Bertoncini CW, Zweckstetter M, Griesinger C, Fernandez CO ( 2009) Structural and mechanistic basis behind the inhibitory interaction of PcTS on alpha-synuclein amyloid fibril formation. Proc Natl Acad Sci USA 106: 2105721062.
  • 30
    Nicoll AJ, Trevitt CR, Tattum MH, Risse E, Quarterman E, Ibarra AA, Wright C, Jackson GS, Sessions RB, Farrow M, Waltho JP, Clarke AR, Collinge J ( 2010) Pharmacological chaperone for the structured domain of human prion protein. Proc Natl Acad Sci USA 107: 1761017615.
  • 31
    Ansari A, Berendzen J, Bowne SF, Frauenfelder H, Iben IE, Sauke TB, Shyamsunder E, Young RD ( 1985) Protein states and proteinquakes. Proc Natl Acad Sci USA 82: 50005004.
  • 32
    Itoh K, Sasai M ( 2004) Dynamical transition and proteinquake in photoactive yellow protein. Proc Natl Acad Sci USA 101: 1473614741.
  • 33
    Cohen FE, Prusiner SB ( 1998) Pathologic conformations of prion proteins. Annu Rev Biochem 67: 793819.
  • 34
    Cohen FE, Pan KM, Huang Z, Baldwin M, Fletterick RJ, Prusiner SB ( 1994) Structural clues to prion replication. Science 264: 530531.
  • 35
    Cohen FE, Prusiner SB, Structural studies of prion proteins. In: Prusiner SB, Ed. ( 1999) Prion biology and diseases. New York: Cold Spring Harbor, pp 191228.
  • 36
    Yamamoto N, Kuwata K ( 2009) Regulating the conformation of prion protein through ligand binding. J Phys Chem B 113: 1285312856.
  • 37
    Telling GC, Parchi P, DeArmond SJ, Cortelli P, Montagna P, Gabizon R, Mastrianni J, Lugaresi E, Gambetti P, Prusiner SB ( 1996) Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science 274: 20792082.
  • 38
    Safar J, Wille H, Itri V, Groth D, Serban H, Torchia M, Cohen FE, Prusiner SB ( 1998) Eight prion strains have PrP(Sc) molecules with different conformations. Nat Med 4: 11571165.
  • 39
    Kawasaki Y, Kawagoe K, Chen CJ, Teruya K, Sakasegawa Y, Doh-ura K ( 2007) Orally administered amyloidophilic compound is effective in prolonging the incubation periods of animals cerebrally infected with prion diseases in a prion strain-dependent manner. J Virol 81: 1288912898.
  • 40
    Li J, Browning S, Mahal SP, Oelschlegel AM, Weissmann C ( 2010) Darwinian evolution of prions in cell culture. Science 327: 869872.
  • 41
    Sawkar AR, Cheng WC, Beutler E, Wong CH, Balch WE, Kelly JW ( 2002) Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci USA 99: 1542815433.
  • 42
    Kanu N, Imokawa Y, Drechsel DN, Williamson RA, Birkett CR, Bostock CJ, Brockes JP ( 2002) Transfer of scrapie prion infectivity by cell contact in culture. Curr Biol 12: 523530.
  • 43
    Montagnier L ( 2010) 25 years after HIV discovery: prospects for cure and vaccine. Virology 397: 248254.
  • 44
    Shafer RW, Vuitton DA ( 1999) Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1. Biomed Pharmacother 53: 7386.
  • 45
    Roberts BE, Duennwald ML, Wang H, Chung C, Lopreiato NP, Sweeny EA, Knight MN, Shorter J ( 2009) A synergistic small-molecule combination directly eradicates diverse prion strain structures. Nat Chem Biol 5: 936946.
  • 46
    Hornemann S, Korth C, Oesch B, Riek R, Wider G, Wuthrich K, Glockshuber R ( 1997) Recombinant full-length murine prion protein, mPrP(23-231): purification and spectroscopic characterization. FEBS Lett 413: 277281.
  • 47
    Goddard TD, Kneller DG ( 2001) SPARKY, version 3. San Francisco: University of California.
  • 48
    Riek R, Hornemann S, Wider G, Billeter M, Glockshuber R, Wuthrich K ( 1996) NMR structure of the mouse prion protein domain PrP(121-231). Nature 382: 180182.
  • 49
    Nishida N, Harris DA, Vilette D, Laude H, Frobert Y, Grassi J, Casanova D, Milhavet O, Lehmann S ( 2000) Successful transmission of three mouse-adapted scrapie strains to murine neuroblastoma cell lines overexpressing wild-type mouse prion protein. J Virol 74: 320325.